Cetera Advisor Networks’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-7,106
Closed -$245K 2136
2022
Q1
$245K Sell
7,106
-2,027
-22% -$71.6K ﹤0.01% 1765
2021
Q4
$400K Sell
9,133
-703
-7% -$33.3K ﹤0.01% 1422
2021
Q3
$499K Buy
9,836
+6
+0.1% +$313 0.01% 1229
2021
Q2
$511K Buy
9,830
+122
+1% +$5.73K 0.01% 1168
2021
Q1
$444K Buy
+9,708
New +$474K 0.01% 940

Other funds holding IDNA

Cetera Advisor Networks's IDNA Position: Q2 2022 in Review

Cetera Advisor Networks sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q2 2022, closing a stake of 7,106 shares — an estimated $245K sold.

Cetera Advisor Networks first reported a position in IDNA in Q1 2021 and held it in 5 quarters. The position peaked at $511K in Q2 2021. 73 funds tracked by Wall St. Rank hold IDNA as of Q2 2022.

  • Cetera Advisor Networks reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q2 2022 after selling out during the quarter.
  • Cetera Advisor Networks sold 7,106 iShares Genomics Immunology and Healthcare ETF shares in Q2 2022, an estimated $245K.
  • Cetera Advisor Networks first reported a position in iShares Genomics Immunology and Healthcare ETF in Q1 2021 and held it in 5 quarters.
  • Cetera Advisor Networks's iShares Genomics Immunology and Healthcare ETF position peaked at $511K in Q2 2021.
  • 73 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q2 2022.

Based on Cetera Advisor Networks's 13F filing for Q2 2022, filed 11 Aug 2022.